JP2004508065A5 - - Google Patents

Download PDF

Info

Publication number
JP2004508065A5
JP2004508065A5 JP2002526418A JP2002526418A JP2004508065A5 JP 2004508065 A5 JP2004508065 A5 JP 2004508065A5 JP 2002526418 A JP2002526418 A JP 2002526418A JP 2002526418 A JP2002526418 A JP 2002526418A JP 2004508065 A5 JP2004508065 A5 JP 2004508065A5
Authority
JP
Japan
Prior art keywords
vector according
antigen
adenyl cyclase
proteinaceous vector
proteinaceous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002526418A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004508065A (ja
Filing date
Publication date
Priority claimed from EP00402562A external-priority patent/EP1188446B1/en
Application filed filed Critical
Publication of JP2004508065A publication Critical patent/JP2004508065A/ja
Publication of JP2004508065A5 publication Critical patent/JP2004508065A5/ja
Pending legal-status Critical Current

Links

JP2002526418A 2000-09-15 2001-09-14 ＣＤ１１ｂ発現細胞に対する分子送達用ベクター Pending JP2004508065A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00402562A EP1188446B1 (en) 2000-09-15 2000-09-15 Proteinaceous vectors for molecule delivery to CD11b expressing cells
PCT/EP2001/011315 WO2002022169A2 (en) 2000-09-15 2001-09-14 VECTORS FOR MOLECULE DELIVERY TO CD11b EXPRESSING CELLS

Publications (2)

Publication Number Publication Date
JP2004508065A JP2004508065A (ja) 2004-03-18
JP2004508065A5 true JP2004508065A5 (https=) 2011-12-01

Family

ID=8173866

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002526418A Pending JP2004508065A (ja) 2000-09-15 2001-09-14 ＣＤ１１ｂ発現細胞に対する分子送達用ベクター

Country Status (16)

Country Link
US (4) US20040001867A1 (https=)
EP (2) EP1188446B1 (https=)
JP (1) JP2004508065A (https=)
KR (2) KR100953364B1 (https=)
AT (2) ATE438409T1 (https=)
AU (2) AU9385501A (https=)
BR (1) BR0113915A (https=)
CA (1) CA2422603A1 (https=)
CZ (1) CZ2003726A3 (https=)
DE (1) DE60042687D1 (https=)
ES (1) ES2331348T3 (https=)
HU (1) HUP0303126A3 (https=)
PL (1) PL208864B1 (https=)
PT (1) PT1188446E (https=)
RU (1) RU2312143C2 (https=)
WO (1) WO2002022169A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2646776B1 (fr) 1989-05-12 1994-06-03 Pasteur Institut Utilisation de preparations vaccinantes a base d'adenyl cyclase ou de bacteries les produisant en tant qu'antigenes protecteurs contre les effets des bordetella
ES2331348T3 (es) 2000-09-15 2009-12-30 Pasteur Institut Vectores proteinicos para el suministro de moleculas a las celulas que expresan cd11b.
EP1489092A1 (en) * 2003-06-18 2004-12-22 Institut Pasteur Modified Bordetella adenylate cyclase comprising or lacking CD11b/CD18 interaction domain and uses thereof
JP2008500271A (ja) * 2003-10-14 2008-01-10 ザ・プロウボウスト・フェロウズ・アンド・スカラーズ・オブ・ザ・カレッジ・オブ・ザ・ホリー・アンド・アンデバイデッド・トリニティ・オブ・クイーン・エリザベス・ニア・ダブリン 免疫介在性疾患の治療および／または予防におけるアデニル酸シクラーゼ
EP2193804B1 (en) 2003-11-21 2015-12-23 Institut Pasteur Recombinant adenylate cyclase toxin of bordetella induces T cell responses against tumoral antigens
PL1576967T3 (pl) 2004-03-18 2008-03-31 Pasteur Institut Rekombinowane białko niosące epitopy ludzkiego wirusa brodawczaka wstawione w białko cyklazy adenylanowej lub jego fragment oraz jego zastosowania terapeutyczne
ES2291071B1 (es) * 2005-06-13 2009-03-16 Proyecto De Biomedicina Cima, S.L. Agentes y metodos basados en el uso del dominio eda de la fibronectina.
ES2331271B1 (es) * 2007-06-29 2010-10-14 Universidad Del Pais Vasco Metodo para la internalizacion de bacterias no invasivas en celulas eucariotas.
CN102046196B (zh) * 2008-05-29 2014-07-30 特朗斯吉有限公司 用于选择患者的生物标志物及相关方法
CN102439146A (zh) 2009-03-23 2012-05-02 巴斯德研究院 适合将免疫原性分子递送到细胞中的突变CyaA多肽及多肽衍生物
PL2233569T3 (pl) 2009-03-23 2015-02-27 Pasteur Institut Zmutowane polipeptydy cyaa i pochodne polipeptydu odpowiednie do dostarczania cząsteczek immunogennych do komórki
GB201003920D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Method of treatment
EP2478915A1 (en) * 2011-01-24 2012-07-25 Genticel CyaA-carried polypeptide(s) and use to induce both therapeutic and prophylactic immune responses
EP2690172A1 (en) 2012-07-23 2014-01-29 Genticel CYAA-based chimeric proteins comprising a heterologous polypeptide and their uses in the induction of immune responses
EP2689786A1 (en) 2012-07-23 2014-01-29 Genticel HPV/CYAA-based chimeric proteins and their uses in the induction of immune responses against HPV infection and HPV-induced disorders
EP2975120A1 (en) 2014-07-17 2016-01-20 Institut Pasteur Monomeric and functional adenylate cyclase CyaA toxin
EP3323426A1 (en) 2016-11-17 2018-05-23 Ecole Nationale Vétérinaire de Toulouse Immunogenic and vaccine compositions for use against bordetella bronchiseptica infection
WO2018091613A1 (en) 2016-11-17 2018-05-24 Ecole Nationale Vétérinaire de Toulouse Immunogenic and vaccine compositions for use against bordetella bronchiseptica infection
EP3342421A1 (en) 2016-12-27 2018-07-04 Genticel Immunogenic composition comprising cyaa-derived polypeptide promoting a th1/th17-oriented immune response
US20200255531A1 (en) * 2017-11-03 2020-08-13 Mackay Memorial Hospital Method for modulation of tumor associated myeloid cells and enhancing immune checkpoint blockade

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2597605B1 (fr) * 1986-04-16 1989-06-23 Merieux Inst Nouveau materiau pour chromatographie d'affinite et son application a la separation et a la purification des antigenes proteiques des bacteries du genre bordetella
FR2601679B1 (fr) * 1986-07-15 1990-05-25 Sanofi Sa Immunotoxines, procede de preparation et compositions pharmaceutiques en contenant
US5182211A (en) 1987-08-07 1993-01-26 Institut Pasteur Plasmid vectors encoding a protein of a picornavirus
US5312902A (en) 1988-06-09 1994-05-17 Institut Pasteur Dimer of the precursor of HIV-2 envelope glycoprotein
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
FR2638169B1 (fr) 1988-10-25 1991-01-11 Pasteur Institut Derives d'adenyl cyclase et leurs utilisations biologiques
EP0406857B1 (en) 1989-07-07 1995-05-24 Takeda Chemical Industries, Ltd. Proteins and production thereof
NO175188C (no) 1990-06-27 1994-09-14 Sjur Olsnes Fremgangsmåte for fremstilling av et peptidkonjugat med evne til å trenge inn i cellecytosol
US5935580A (en) * 1992-04-21 1999-08-10 Institut Pasteur Recombinant mutants for inducing specific immune responses
WO1993021324A1 (en) * 1992-04-21 1993-10-28 Institut Pasteur Recombinant mutants for inducing specific immune responses
JP4256932B2 (ja) * 1995-06-07 2009-04-22 ジョエル ケイ． スワデッシュ 抗原プロセシング細胞標的複合体
US5821122A (en) 1995-06-07 1998-10-13 Inserm (Institute Nat'l De La Sante Et De La Recherche . .) Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof
AU2322097A (en) 1996-03-27 1997-10-17 Ortho Pharmaceutical Corporation Lyophilized pulmonary surfactant peptide compositions
US6333154B1 (en) * 1997-12-04 2001-12-25 Institut Pasteur Bacterial multi-hybrid system and applications thereof
US6673914B1 (en) 1998-01-22 2004-01-06 John Wayne Cancer Institute Human tumor-associated gene
CN100352921C (zh) * 1999-05-06 2007-12-05 威克福雷大学 用于鉴定引起免疫反应的抗原的组合物和方法
CN1402782A (zh) 1999-10-19 2003-03-12 路德维哥癌症研究院 Mage－a12抗原肽及其应用
ES2331348T3 (es) 2000-09-15 2009-12-30 Pasteur Institut Vectores proteinicos para el suministro de moleculas a las celulas que expresan cd11b.
EP1489092A1 (en) 2003-06-18 2004-12-22 Institut Pasteur Modified Bordetella adenylate cyclase comprising or lacking CD11b/CD18 interaction domain and uses thereof
JP2008500271A (ja) 2003-10-14 2008-01-10 ザ・プロウボウスト・フェロウズ・アンド・スカラーズ・オブ・ザ・カレッジ・オブ・ザ・ホリー・アンド・アンデバイデッド・トリニティ・オブ・クイーン・エリザベス・ニア・ダブリン 免疫介在性疾患の治療および／または予防におけるアデニル酸シクラーゼ
US20070026022A1 (en) 2004-11-19 2007-02-01 Gilles Dadaglio Recombinant adenylate cyclase toxin of Bordetella induces T cell responses against tumoral antigens
EP2193804B1 (en) 2003-11-21 2015-12-23 Institut Pasteur Recombinant adenylate cyclase toxin of bordetella induces T cell responses against tumoral antigens
PL1576967T3 (pl) 2004-03-18 2008-03-31 Pasteur Institut Rekombinowane białko niosące epitopy ludzkiego wirusa brodawczaka wstawione w białko cyklazy adenylanowej lub jego fragment oraz jego zastosowania terapeutyczne
EP1894941A1 (en) 2006-09-01 2008-03-05 Institut Pasteur Treatment of cervical carcinoma with a recombinant adenylate cyclase carrying HPV antigens
US8017132B2 (en) * 2009-03-23 2011-09-13 Institut Pasteur Mutant CyaA polypeptides and polypeptide derivatives suitable for the delivery of immunogenic molecules into a cell

Similar Documents

Publication Publication Date Title
JP2004508065A5 (https=)
Misstear et al. Targeted nasal vaccination provides antibody-independent protection against Staphylococcus aureus
Liu et al. Guiding principles in the design of molecular bioconjugates for vaccine applications
Hanagata CpG oligodeoxynucleotide nanomedicines for the prophylaxis or treatment of cancers, infectious diseases, and allergies
Lynn et al. In vivo characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity
Zaks et al. Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes
Huang et al. In vivo cytotoxic T lymphocyte elicitation by mycobacterial heat shock protein 70 fusion proteins maps to a discrete domain and is CD4+ T cell independent
Warrier et al. Engineering anti-cancer nanovaccine based on antigen cross-presentation
CN100391542C (zh) 向抗原呈递细胞递送基因的药物组合物及其用途
Lockner et al. Flagellin as carrier and adjuvant in cocaine vaccine development
CN1441676B (zh) 用配体-免疫原缀合物治疗的方法
Li et al. Messenger RNA-based therapeutics and vaccines: what’s beyond COVID-19?
US20180104354A1 (en) Chimeric antigen receptor t cell switches and uses thereof
JP2022101576A (ja) スギ花粉エピトープを封入するｔｉｍｐ（組織性メタロプロテアーゼ阻害因子）
Tyne et al. TLR2-targeted secreted proteins from Mycobacterium tuberculosis are protective as powdered pulmonary vaccines
Skakuj et al. Chemically tuning the antigen release kinetics from spherical nucleic acids maximizes immune stimulation
TW200846370A (en) Agents that engage antigen-presenting cells through dendritic cell asialoglycoprotein receptor (DC-ASGPR)
Li et al. Cancer nanoimmunotherapy using advanced pharmaceutical nanotechnology
Kreitman Recombinant immunotoxins for the treatment of chemoresistant hematologic malignancies
JP6456306B2 (ja) ｉＮＫＴ細胞の活性化
RU2003110574A (ru) Векторы для доставки молекул к экспрессирующим cd11b клеткам
Hashemzadeh et al. Vaccines based on virus-like nano-particles for use against Middle East Respiratory Syndrome (MERS) coronavirus
Clauson et al. The content of CpG-DNA in antigen-CpG conjugate vaccines determines their cross-presentation activity
Zhao et al. Cyclic dinucleotide self-assembled nanoparticles as a carrier-free delivery platform for STING-mediated cancer immunotherapy
Hu et al. Pam3CSK4-CDGSF augments antitumor immunotherapy by synergistically activating TLR1/2 and STING